Skip to content
DataLookout
Menu

NCT06695845

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 20 versions: 8 with changes below, 12 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words
    • Trial sites expanded: 28 → 42 locations
    • Secondary endpoints: details revised at 1 of 19 entries
  2. Minor Trial sites expanded: 21 → 28 locationsv18
  3. Minor Study sites: 20 to 21v8
  4. Minor Study sites: 18 to 20v7
  5. Notable Eligibility criteria expanded, about 65 words
    • Study sites: 14 to 18
    v6
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 2 to 14
    • Start date changed from estimate of Dec 31, 2024 to Jan 14, 2025
    v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 29, 2024 to Dec 31, 2024
    • Study sites: 1 to 2
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR
Timeframe: Up to 2.5 years

Secondary (19)

Duration of Response (DOR) Per RECIST Version 1.1, as assessed by ICR
cORR by RECIST Version 1.1, as assessed by Investigator
Duration of Response (DOR) Per RECIST Version 1.1, as assessed by Investigator
Time to Response (TTR), as assessed by ICR
Time to Response (TTR), as assessed by Investigator
Show 14 moreShow less
Disease control rate (DCR), as assessed by ICR
Disease control rate (DCR), as assessed by Investigator
Progression Free Survival (PFS), as assessed by ICR
Progression Free Survival (PFS), as assessed by Investigator
Overall Survival (OS)
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) As Graded by NCI CTCAE Version 5.0
Number of Participants With Dose Reductions
Number of Participants Discontinuing Study Treatment Due to TEAEs
Serum Concentrations of Zanidatamab
Number of Participants Positive for Anti-drug Antibodies to Zanidatamab
Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE)
Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library
Percentage of all treated participants reporting overall side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)
Percentage of time when participants on treatment reported a high side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)

Arms and interventions

Zanidatamab treatment armExperimental

Eligible participants receiving zanidatamab treatment

Drugs: Zanidatamab

Sites

42 sites in 4 countries

United States 19, South Korea 10, Spain 8, Georgia 5